PF-00562271 Besylate

Catalog No.S2672 Synonyms: PF-562271 Besylate

PF-00562271 Besylate Chemical Structure

Molecular Weight(MW): 665.66

PF-00562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.

Size Price Stock Quantity  
USD 270 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 6 Publications

4 Customer Reviews

  • Mol Ther 2012 20(5), 972-83. PF-00562271 Besylate purchased from Selleck.

    Pharmacological inhibition of optoFAK with the ATP-competitive FAK inhibitor PF-00562271. OptoFAK expressing SC4 cells were serum-starved for 24 h in the absence or presence of PF-00562271 (1 mM) before being illuminated for 10 min with blue light (451 nm, 2 μmol m-2 s-1) or kept in the dark.

    Cell Signal, 2018, 42:176-183. PF-00562271 Besylate purchased from Selleck.

  • The migration index enhanced by CX3CL1 was dramatic reduced using Bosutinib and PF-00562271. CX3CL1-only group as control. Scale bar = 200 μm. The experiments were repeated three times. *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001.

    J Cancer, 2018, 9(19):3603-3612. PF-00562271 Besylate purchased from Selleck.

    SGC-7901 and MGC-803 cells were treated with OLFM4-sh lentivirus or FAK inhibitor (PF) alone, or co-treated with OLFM4-sh lentivirus and PF. Cellular invasive ability was measured by transwell assay after indicated treatment. Data are expressed as mean ± standard deviation from three independent experiments. One was analysis of variance (ANOVA) with Bonferroni T post-test was used to analysis the data. *P < 0.05, ***P < 0.001; ##P < 0.01, ###P < 0.001 VS. OLFM4-sh group.

    BMB Rep, 2015, 48(11):630-5. PF-00562271 Besylate purchased from Selleck.

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Description PF-00562271 Besylate is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Targets
FAK [1]
(Cell-free assay)
PYK2 [1]
(Cell-free assay)
CDK2/CyclinE [1]
(Cell-free assay)
CDK3/CyclinE [1]
(Cell-free assay)
CDK1/CyclinB [1]
(Cell-free assay)
1.5 nM 13 nM 30 nM 47 nM 58 nM
In vitro

PF-562271 Besylate shows the selective inhibitory effects on FAK and Pyk2 tyrosine kinase activity with IC50 of 1.5 nM and 14 nM, respectively. And in cell-based assays, the IC50 of PF-562271 is shown to be 5 nM for FAK, which is more selective compared to other kinase targets. [1] In 2 dimensional (2D) cultures, PF-562271 results in a dose-dependent cell proliferation inhibition in FAK WT, FAK−/− and FAK kinase-deficient (KD) cells with IC50 of 3.3 μM, 2.08 μM and 2.01 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 cell NVLHe2FPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWPJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI4PjZizszN MkDtV2FPT0WU
human SW982 cell NELpO3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NI\iOFBKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Ojh{IN88US=> MlHvV2FPT0WU
human KM12 cell NFHZenJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGtOOTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkO4OVU4KM7:TR?= M{j5dnNCVkeHUh?=
human COLO-205 cell NWTS[WhLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3jmbGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz2yNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR6NkW4JO69VQ>? M{[4UHNCVkeHUh?=
human COLO-829 cell NEC5XlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlvMTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiyPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzZzN{[g{txO M2[wenNCVkeHUh?=
human MG-63 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTlNJNKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45ODZ|NzFOwG0> NGTaS3VUSU6JRWK=
human IGROV-1 cell NYXFPYhUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPtTY5pcWKrdHnvckBw\iCqdX3hckBKT1KRVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45OTB|ODFOwG0> Mon6V2FPT0WU
human NCI-H650 cell NFLxfmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45OzF3NDFOwG0> NEKx[4pUSU6JRWK=
human RT-112 cell NEnkeXJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUDF[oZTUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl6NE[g{txO NVrrdHY6W0GQR1XS
human BCPAP cell M{jHfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXfVelh1UW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODF{OEig{txO MXTTRW5ITVJ?
ALL-PO cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzYTY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAyPTh2IN88US=> M{TlXHNCVkeHUh?=
human KYSE-270 cell M121TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXu2PWRLUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMES3NVQh|ryP M1\Yc3NCVkeHUh?=
human 8305C cell NXK1T4ZFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{GyXGlvcGmkaYTpc44hd2ZiaIXtZY4hQDNyNVOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA6QTB2IN88US=> M4r2UnNCVkeHUh?=
NCI-H810 cell Mn6yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlTUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTB5N{[g{txO M1XWcHNCVkeHUh?=
human CAL-33 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;BN25KdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTJ7M{ig{txO M3fWV3NCVkeHUh?=
human AN3-CA cell NX3vfYs2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVPxfYdmUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJzOE[3JO69VQ>? MnjJV2FPT0WU
human NKM-1 cell MmfwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{fpNGlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI4PTB4IN88US=> NHrCTlBUSU6JRWK=
human BPH-1 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFfvZ4dKdmirYnn0bY9vKG:oIHj1cYFvKEKSSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zQDd4NjFOwG0> NV;ZNZFKW0GQR1XS
human MES-SA cell Mln1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjvZ5FKdmirYnn0bY9vKG:oIHj1cYFvKE2HUz3TRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzB4OEKg{txO MkXaV2FPT0WU
human CAL-62 cell NWHJenpHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH\sTpNKdmirYnn0bY9vKG:oIHj1cYFvKEODTD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzF7MEmg{txO NXTTTWVlW0GQR1XS
human KYSE-150 cell MnLQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXrLXVNtUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{WyN|Yh|ryP NUjVb|B5W0GQR1XS
human SK-UT-1 cell NXPtbGUyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4r3OmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvVWStNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDR4NEeg{txO NH7RelJUSU6JRWK=
human HUTU-80 cell NHzvcnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLi[GlNUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS52NEi4OkDPxE1? Moj2V2FPT0WU
human SIG-M5 cell NUm1eWpxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGi3bXHuJHNKTy2PNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFg1QDdizszN MmfPV2FPT0WU
human AGS cell MmnNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNUKxNlQh|ryP NIK4RpdUSU6JRWK=
human ST486 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mnv2TY5pcWKrdHnvckBw\iCqdX3hckBUXDR6NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVMzPzhizszN M4W3WnNCVkeHUh?=
human HSC-2 cell MofKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NInIPYtKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42Ozl3IN88US=> NFvzSlBUSU6JRWK=
human BC-1 cell NHjBVlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHm3dGtKdmirYnn0bY9vKG:oIHj1cYFvKEKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYyPjZ2IN88US=> MV7TRW5ITVJ?
human CGTH-W-1 cell NF3nOGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVuye4ZoUW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNkG2O|kh|ryP NEKxbI1USU6JRWK=
human MZ1-PC cell NXry[5VIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M13tdWlvcGmkaYTpc44hd2ZiaIXtZY4hVVpzLWDDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OjNzMjFOwG0> M3f5bHNCVkeHUh?=
human SW1710 cell M1zmS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2rXVGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OjZ{ODFOwG0> NWrJbJU6W0GQR1XS
human EW-13 cell M1fneGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFO3V5VKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OzR4NjFOwG0> NG\DZ|NUSU6JRWK=
human U251 cell M3\XPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPMPYttUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44PDB|MTFOwG0> MVPTRW5ITVJ?
human NCI-H460 cell M3n4XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlPFTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODR6M{mg{txO MmTnV2FPT0WU
human DU-4475 cell M172XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlX1TY5pcWKrdHnvckBw\iCqdX3hckBFXS12NEe1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yPDd3OTFOwG0> NYCx[5dCW0GQR1XS
human MFE-296 cell NWrhbGNHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M17zZWlvcGmkaYTpc44hd2ZiaIXtZY4hVU[HLUK5OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDd5OUKg{txO NGjCfZNUSU6JRWK=
human DU-145 cell MlHYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOFkyOThizszN MULTRW5ITVJ?
human MDA-MB-231 cell NEP1RWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{K3VWlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNEm1O|Ih|ryP MmjQV2FPT0WU
human SNU-387 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS1|OEegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlUzQDJizszN MmXQV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo In several human s.c. xenograft models, PF-562271 exhibits dose-dependent tumor growth inhibition, and produces maximum tumor inhibition for PC-3M, BT474, BxPc3, and LoVo ranging from 78% to 94% inhibition at doses of 25 to 50 mg/kg twice daily, without weight loss, morbidity, or death. [1] PF-562271 (25 mg/kg by p.o.) leads to a significant decrease in tumor progression in both subcutaneous and bone metastasis PC3M-luc-C6 xenograft models. [3] In a Huh7.5 hepatocellular carcinoma xenograft model, combination therapy of sunitinib and PF-562271 targets angiogenesis and tumor aggressiveness, and produces more significant anti-tumor effect than single agent by blocking tumor growth and impacting the ability of the tumor to recover upon withdrawal of the therapy. [4]

Protocol

Kinase Assay:

[1]

+ Expand

Recombinant kinase assay and enzyme kinetics :

Briefly, purified-activated FAK kinase domain (amino acid 410–689) is reacted with 50 μM ATP and 10 μg per well of a random peptide polymer of Glu and Tyr, p(Glu/Tyr), in kinase buffer [50 mM HEPES (pH 7.5), 125 mM NaCl, and 48 mM MgCl2] for 15 minutes. Phosphorylation of p(Glu/Tyr) is challenged with serially diluted PF-562271 at 1/2-Log concentrations starting at a top concentration of 1 μM. Each concentration is tested in triplicate. Phosphorylation of p(Glu/Tyr) is detected with a general antiphospho-tyrosine (PY20) antibody followed by horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody. HRP substrate is added, and absorbance readings at 450 nm are obtained after addition of stop solution (2 M H2SO4). IC50 values are determined using the Hill-Slope Model. Broad kinase selectivity profiling is performed in house and by using the KinaseProfiler Selectivity Screening Service available through UpState Biotechnology.
Cell Research:

[2]

+ Expand
  • Cell lines: Squamous cell carcinoma (SCC)
  • Concentrations: 0 to 1 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are plated for 48 hours before addition of PF-562271. After 3 days cells are fixed by addition of ice cold 25% trichloroacetic acid (TCA) solution prior to staining with Sulforhodamine B (SRB) dye solution. Plates are washed with 1% glacial acetic acid, air-dried and resuspended in 10 mM Tris buffer, pH 10.5 before reading absorbance at 540 nm. Curve fitting and generation of IC50 values is carried out using GraphPad Prism 4 software from six replicates.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: PC-3M, BT474, BxPc3, LoVo, U87MG, H125 and H460 cells are injected s.c. into the right flank of athymic female mice .
  • Formulation: PF-562271 is dissolved in 5% Gelucire.
  • Dosages: ≤100 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (21.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 665.66
Formula

C21H20F3N7O3S.C6H6O3S

CAS No. 939791-38-5
Storage powder
in solvent
Synonyms PF-562271 Besylate

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00666926 Completed Head and Neck Neoplasm|Prostatic Neoplasm|Pancreatic Neoplasm Verastem Inc. December 2005 Phase 1
NCT00666926 Completed Head and Neck Neoplasm|Prostatic Neoplasm|Pancreatic Neoplasm Verastem Inc. December 2005 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We are planning both in vitro and in vivo experiments and want to know how to reconstitute the drug for these purposes?

  • Answer:

    PF-00562271 has poor solubility in DMSO and water. Its solubility in DMSO is only 0.4mg/ml. In a previous literature report (http://www.ncbi.nlm.nih.gov/pubmed/18339875), the author used 5% Gelucire to formulate the compound. You can also consider other co-solvents such as PEG400, CMC, Tween80, and Captisol.

  • Question 2:

    Can you provide with a few common vehicles for PF-00562271, S2672 for use as oral gavage?

  • Answer:

    S2672 PF-00562271 can be dissolved in 0.5% CMC Na at 30 mg/ml as a suspension. If 4% DMSO can be used in your experiment, it will help dissolving the suspension more homogeneously.

FAK Signaling Pathway Map

Related FAK Products0

Tags: buy PF-00562271 Besylate | PF-00562271 Besylate supplier | purchase PF-00562271 Besylate | PF-00562271 Besylate cost | PF-00562271 Besylate manufacturer | order PF-00562271 Besylate | PF-00562271 Besylate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID